Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis

por Wada, Russell, Kleijn, Huub Jan, Zhang, Lu, Chen, Shang‐Chiung
Publicado 2023

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

por Singh, Pratap, Gao, Xiang, Kleijn, Huub Jan, Bellanti, Francesco, Pelto, Ryan
Publicado 2021

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

por Monteleone, Jonathan P. R., Gao, Xiang, Kleijn, Huub Jan, Bellanti, Francesco, Pelto, Ryan
Publicado 2021

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

por Jiang, Xuemin, Wada, Russ, Poland, Bill, Kleijn, Huub Jan, Fan, Bin, Liu, Guowen, Liu, Hua, Kapsalis, Stephanie, Yang, Hua, Le, Kha
Publicado 2021

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

por Li, Chi‐Chung, Voss, Tiffini, Kowalski, Ken, Yang, Bei, Kleijn, Huub Jan, Jones, Christopher J., Bosch, Rolien, Michelson, David, DeAngelis, Matthew, Xu, Yang, Xie, Iris, Kothare, Prajakti A.
Publicado 2020

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

por Muccino, David R., Morice, Alyn H., Birring, Surinder S., Dicpinigaitis, Peter V., Pavord, Ian D., Assaid, Christopher, Kleijn, Huub Jan, Hussain, Azher, La Rosa, Carmen, McGarvey, Lorcan, Smith, Jaclyn A.
Publicado 2020

Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling

por Marathe, Dhananjay D., Jauslin, Petra M., Kleijn, Huub Jan, de Miranda Silva, Carolina, Chain, Anne, Bateman, Thomas, Shaw, Peter M., Abraham, Anson K., Kauh, Eunkyung A., Liu, Yanfang, Perini, Rodolfo F., de Alwis, Dinesh P., Jain, Lokesh
Publicado 2023